Skip Navigation LinksHome > September 2013 - Volume 41 - Issue 9 > A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Stu...
Text sizing:
A
A
A
Critical Care Medicine:
doi: 10.1097/CCM.0b013e31828e9b03
Feature Articles

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*

Vincent, Jean-Louis MD, PhD, FCCM1; Ramesh, Mayakonda K. MS2; Ernest, David MBBS3; LaRosa, Steven P. MD4; Pachl, Jan MD, PhD5; Aikawa, Naoki MD, DMSc, FACS6; Hoste, Eric MD, PhD7; Levy, Howard MB, BCh, PhD8; Hirman, Joe PhD9; Levi, Marcel MD, PhD10; Daga, Mradul MD, FCCP11; Kutsogiannis, Demetrios J. MD, MHS12; Crowther, Mark MD, MSc, FRCPC13; Bernard, Gordon R. MD14; Devriendt, Jacques MD15; Puigserver, Joan Vidal MD16; Blanzaco, Daniel U. MD17; Esmon, Charles T. PhD18; Parrillo, Joseph E. MD19; Guzzi, Louis MD, FCCM20; Henderson, Seton J. MB, ChB21; Pothirat, Chaicharn MD, FCCP22; Mehta, Parthiv MD23; Fareed, Jawed PhD, FAHA24; Talwar, Deepak MD, DM, DNB25; Tsuruta, Kazuhisa PhD26; Gorelick, Kenneth J. MD, FCCP27; Osawa, Yutaka MPharm26; Kaul, Inder MD, MPH26

Supplemental Author Material
Collapse Box

Abstract

Objectives:

To determine the safety and efficacy of recombinant thrombomodulin (ART-123) in patients with suspected sepsis-associated disseminated intravascular coagulation.

Design:

Phase 2b, international, multicenter, double-blind, randomized, placebo-controlled, parallel group, screening trial.

Setting:

Two hundred and thirty-three ICUs in 17 countries.

Patients:

All adult patients admitted with sepsis and suspected disseminated intravascular coagulation as assessed using a modified International Society on Thrombosis and Hemostasis score.

Interventions:

Patients were randomized to receive IV ART-123 (0.06 mg/kg/d) for 6 days or placebo, in addition to standard of care. The primary endpoint was reduction in mortality. Secondary endpoints included reversal of overt disseminated intravascular coagulation and reduction in disease severity.

Measurements and Main Results:

A total of 750 patients were randomized, nine of whom did not receive the allocated treatment so that 371 patients received ART-123 and 370 received placebo. There were no meaningful differences between the two groups in any of the baseline variables. Twenty-eight-day mortality was 17.8% in the ART-123 group and 21.6% in the placebo group (Cochran–Mantel–Haenszel two-sided p value of 0.273 in favor of ART-123, which met the predefined statistical test for evidence suggestive of efficacy). There were no statistically significant differences in event-free and alive days between the two groups. d-dimer, prothrombin fragment F1.2 and TATc concentrations were lower in the ART-123 group than in the placebo group. There were no differences between the two groups in organ function, inflammatory markers, bleeding or thrombotic events or in the development of new infections. In post hoc analyses, greatest benefit from ART-123 was seen in patients with at least one organ system dysfunction and an international normalized ratio greater than 1.4 at baseline.

Conclusions:

ART-123 is a safe intervention in critically ill patients with sepsis and suspected disseminated intravascular coagulation. The study provided evidence suggestive of efficacy supporting further development of this drug in sepsis-associated coagulopathy including disseminated intravascular coagulation. Future study should focus on using ART-123 in the subgroup of patients most likely to respond to this agent.

Copyright © 2013 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.